Drüeke T, Bordier P J, Man N K, Jungers P, Marie P
Kidney Int. 1977 Apr;11(4):267-74. doi: 10.1038/ki.1977.40.
The influence of a dialysate calcium concentration of 8.0 mg/100 ml (treatment period 2) vs. 7.0 mg/100 ml (treatment period 1) on plasma calcium, phosphorus, serum immunoreactive parathyroid hormone (iPTH), bone histology, intestinal calcium absorption, and calcium transfer across the dialysis membrane was investigated in six patients with renal osteodystrophy undergoing intermittent hemodialysis. During the periods 1 and 2, the plasma calcium changes before and after dialysis were not significantly different. A significant increase in mean postdialysis plasma calcium level was observed during both periods when compared to mean predialysis level. A significant, inverse relation was found between predialysis plasma calcium and the increase in plasma calcium during hemodialysis runs. Calcium transfer across the dialysis membrane and fractional intestinal absorption of calcium in the postdialysis state were determined in four out of the six patients. During period 2, calcium transfer was higher in all four patients but intestinal calcium absorption was moderately higher only in one and strikingly lower in the remaining three patients when compared to period 1. Although brought up to 8.0 mg/100 ml, this higher dialysate calcium significantly decreased the level of serum iPTH only in one out of the six patients; in this patient, osteoclast count, active resorption surface, and periosteocytic osteolysis decreased. In a second patient, although the level of serum iPTH seemed to decrease markedly osteoclastic and osteocytic resorption did not change. In the remaining four patients, the level of serum iPTH was unchanged and bone resorption parameters were found unchanged or aggravated. It is concluded that providing additional calcium (using a dialysate calcium concentration of 8.0 mg/100 ml), the goal of which was to decrease secondary hyperparathyroidism, proved to be successful only in one patient and failed to do so in the five others. Secondary hyperparathyroidism was even found aggravated in three of them. Thus, the use of a dialysate calcium concentration of 8.0 mg/100 ml did not result in any advantage over that of 7.0 mg/100 ml in five out of six patients studied.
在6例接受间歇性血液透析的肾性骨营养不良患者中,研究了透析液钙浓度8.0mg/100ml(治疗期2)与7.0mg/100ml(治疗期1)对血浆钙、磷、血清免疫反应性甲状旁腺激素(iPTH)、骨组织学、肠道钙吸收以及钙通过透析膜转运的影响。在第1期和第2期,透析前后血浆钙的变化无显著差异。与透析前平均水平相比,两期透析后血浆钙平均水平均显著升高。透析前血浆钙与血液透析过程中血浆钙的升高之间存在显著的负相关。在6例患者中的4例中测定了透析后状态下钙通过透析膜的转运及肠道钙的分数吸收。在第2期,与第1期相比,所有4例患者的钙转运均较高,但仅1例患者的肠道钙吸收中度升高,其余3例患者的肠道钙吸收显著降低。尽管透析液钙浓度提高到了8.0mg/100ml,但这种较高的透析液钙仅使6例患者中的1例血清iPTH水平显著降低;在该患者中,破骨细胞计数、活跃吸收表面和骨膜下骨溶解减少。在第2例患者中,尽管血清iPTH水平似乎明显降低,但破骨细胞和骨细胞吸收未发生变化。在其余4例患者中,血清iPTH水平未改变,且骨吸收参数未改变或加重。结论是,提高钙含量(使用8.0mg/100ml的透析液钙浓度),目的是降低继发性甲状旁腺功能亢进,仅在1例患者中成功,在其他5例患者中未成功。甚至在其中3例患者中发现继发性甲状旁腺功能亢进加重。因此,在所研究的6例患者中的5例中,使用8.0mg/100ml的透析液钙浓度与7.0mg/100ml相比没有任何优势。